並前往https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-new-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines-recommendation-for-sacituzumab-govitecan-hziy-trodelvy-in-second-line-and-later-metastatic-triple-negative-breast-cancer